Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MGLL | Q99685 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10595799 | 0.83 | POLB (0.73) | POLBMGLLSMN1; SMN2NPC1RAB9A | |
| Benzyl Phenylcarbamate SCHEMBL1222943 | 0.83 | POLB (0.78) | POLBMGLLSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1336033 | 0.83 | POLB (0.60) | POLBMGLLSMN1; SMN2NPC1RAB9A | |
| SCHEMBL10494592 | 0.83 | POLB (0.68) | POLBMGLLSMN1; SMN2NPC1RAB9A | |
| SCHEMBL7378530 | 0.82 | ROCK2 (0.59) | POLBMGLLSMN1; SMN2NPC1RAB9A | |
| SCHEMBL16992893 | 0.80 | POLB (0.57) | POLBMGLLBCHEACHE | |
| SCHEMBL16992879 | 0.80 | POLB (0.57) | POLBMGLLMAPTBCHEACHE | |
| SCHEMBL3795024 | 0.79 | POLB (0.68) | POLBMGLLSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1334862 | 0.79 | POLB (0.88) | POLBMGLLSMN1; SMN2NPC1RAB9A | |
| SCHEMBL7371074 | 0.79 | ROCK2 (0.59) | POLBMGLLSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | claimed |
| EP-2313094-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | AstraZeneca AB (SE) | 2011-04-27 | — | — | EP | claimed |
| WO-2009147216-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | claimed |
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| EP-2313094-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | AstraZeneca AB (SE) | 2011-04-27 | — | — | EP | disclosed |
| WO-2009147216-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | GPR119, GLP1R, ADIPOR1 | POLB 4125/4885MGLL 654/4885SMN1; SMN2 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.